NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...

Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Tuesday, March ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been fil ...

Friday, Guggenheim Securities downgraded Neumora Therapeutics (NASDAQ: NMRA) stock from Buy to Neutral, in the wake of recent developments in the pharmaceutical industry. The downgrade followed an ...

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

Neumora Therapeutics (NMRA) surprised investors in its Q4 2024 earnings call by reporting an earnings per share (EPS) of -$0.37, surpassing the forecasted -$0.62. This unexpected result led to a ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...